Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Omthera submitted an NDA to FDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels >=500
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury